BioPharmSignal logoBioPharmSignal

Biotech News

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Milestone Pharmaceuticals Inc. (MIST)Milestone Pharmaceuticals Inc.Company update

MONTREAL and CHARLOTTE, N.C., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards, in the form of a total of 33,000 options (the “Options”) to purchase the Company’s common shares,

Related news

MISTMilestone Pharmaceuticals Inc.2026-11-03 13:00 EST

Milestone Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 13, 2026

MISTMilestone Pharmaceuticals Inc.2026-10-19 12:00 EST

Milestone Pharmaceuticals Announces Clinical Data Presentations at Upcoming Cardiology Conferences

NAMSNewAmsterdam Pharma2026-11-06 21:01 EST

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MLYSMineralys Therapeutics2026-11-06 13:00 EST

Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

SGMTSagimet Biosciences2026-10-29 11:00 EST

Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SGMTSagimet Biosciences2026-08-17 20:28 EST

Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MLYSMineralys Therapeutics2026-08-13 20:05 EST

Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

LXRXLexicon Pharmaceuticals2026-08-24 12:30 EST

Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851

RYTMRhythm Pharmaceuticals2026-11-04 13:00 EST

Rhythm Pharmaceuticals Announces NICE Guidance for IMCIVREE® (Setmelanotide) Updated to Include Adults Living with Bardet-Biedl Syndrome

LXRXLexicon Pharmaceuticals2026-10-29 12:30 EST

Lexicon Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026

View all latest news

Milestone Pharmaceuticals Inc.

Self-Administered Cardiac Rescue Therapy Milestone Pharmaceuticals develops rapid-onset nasal therapies for episodic cardiovascular conditions that patients can administer outside a medical setting. CARDAMYST CARDAMYST is an FDA-approved etripamil nasal spray that adults can self-administer to convert symptomatic paroxysmal...

Recent company news

MISTMilestone Pharmaceuticals Inc.2026-11-04 01:45 EST

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MISTMilestone Pharmaceuticals Inc.2026-11-03 13:00 EST

Milestone Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 13, 2026

MISTMilestone Pharmaceuticals Inc.2026-11-02 13:00 EST

New Data Presented at AHA Scientific Sessions 2026 Demonstrate That CARDAMYST® (etripamil) Nasal Spray Converted Recurrent PSVT to Normal Heart Rhythm in Patients with Prior Catheter Ablation

MISTMilestone Pharmaceuticals Inc.2026-10-19 12:00 EST

Milestone Pharmaceuticals Announces Clinical Data Presentations at Upcoming Cardiology Conferences

MISTMilestone Pharmaceuticals Inc.2026-10-09 12:00 EST

Milestone Pharmaceuticals Announces First European Study Participant Enrolled in ReVeRA-301 Phase 3 Clinical Trial

Stock data

Close
0.69 USD
Market cap
164.34M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States